Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - brimonidine tartrate, quantity: 2 mg/ml; brinzolamide, quantity: 10 mg/ml - eye drops, suspension - excipient ingredients: propylene glycol; boric acid; mannitol; tyloxapol; sodium chloride; sodium hydroxide; purified water; carbomer 974p; hydrochloric acid; benzalkonium chloride - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515), brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brinzolamide 10 mg in 1 ml - simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. simbrinza is contraindicated in patients who are hypersensitive to any component of this product. simbrinza is contraindicated in neonates and infants (under the age of two years) [see use in specific populations (8.4)]. developmental toxicity studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 60, and 120 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. in rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/kg/day (180 times the recommended

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, brimonidine tartrate - ocular hypertension; glaucoma, open-angle - ophthalmologicals - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Israel - English - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops, suspension - brimonidine tartrate 2 mg/ml; brinzolamide 10 mg/ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Israel - English - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops suspension - brimonidine tartrate 2 mg / 1 ml; brinzolamide 10 mg / 1 ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Kenya - English - Pharmacy and Poisons Board

novartis pharma ag, litchtstrasse 35, 4056 basel,… novartis pharma ag, litchtstrasse 35, 4056 basel, - brinzolamide/brimonidine tartrate - eye drops, suspension - brinzolamide 10mg/ml, brimonidine tartrate… - brinzolamide combinations

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - brimonidine tartrate; brinzolamide - eye drops - 2mg/1ml ; 10mg/1ml

Kenya - English - Pharmacy and Poisons Board

brinzolamide usp and brimonidine tartrate bp - ophthalmic suspension - brinzolamide usp 1% and brimonidine tartrate bp… - brinzolamide combinations

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - brinzolamide; brimonidine tartrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - brimonidine tartrate; brinzolamide -